Visiongain Publishes Capillary Blood Collection Devices Market Report 2020-2030

02 August 2020
Pharma

Visiongain has launched a new pharma report Capillary Blood Collection Devices Market Report 2020-2030: Prospects by Material (Ceramic, Glass, Plastic, Stainless Steel), Product (Lancets, Micro-Container Tubes, Micro-Hematocrit Tubes, Warming Devices, Others), Applications (Comprehensive Metabolic Panel (CMP) Tests, Dried Blood Spot Tests, Liver Panel/Liver Profile/Liver Function Test, Plasma/Serum Protein Tests, Whole Blood Tests), End Users (Blood Donation Centers, Diagnostic Centers, Home Diagnosis, Hospitals and Clinics, Pathology Laboratories), and Geography.

The global capillary blood collection devices market is projected to grow at a lucrative CAGR of ~xx% and anticipated to surpass USD xx billion by 2030.

The increasing number of surgeries, rising incidences, growing prevalence of various diseases & advancing technology are some of the major factors driving the growth of the global capillary blood collection market. Chronic diseases are a major healthcare issue with more than half of the U.S. adult population suffering from chronic conditions, contributing to over 75% of the nation's overall healthcare costs. As a result, increasing numbers of chronic & infectious diseases are creating a significant revenue generation opportunity for diagnostic testing methods.

The number of non-communicable & infectious diseases has risen tremendously over the past few decades. Rapid urbanization, growing poverty in most developing and underdeveloped economies, antimicrobial resistance, and rising food-borne disease prevalence are some of the factors that are leading to their increased prevalence. Due to the introduction of innovations such as bioanalytical tools, biosensors, novel assay formats, and other complementary testing techniques, Point of Care (PoC) diagnostics has seen tremendous growth in the recent past. Also, the development of molecular diagnostics has allowed rapid diagnosis at a lower cost.

Capillary blood facilitates the collection of devices through the use of PoC diagnostics to allow rapid hematology tests. This form of sample collection is less invasive, cheaper than venous and arterial blood collection, and does not require trained blood drawing professionals. This approach has become the preferred mode of testing in remote & ambulatory healthcare settings, in combination with PoC diagnostics. Also, owing to several advantages, these are used in the pediatric and adult population for different hematology tests. Therefore, the use of capillary blood collection tools is expected to increase shortly with the growing adoption of rapid POC diagnostics.

In the year 2018, the North American capillary blood collection devices market dominated the global market with maximum share. The factors responsible for its dominance are high use of advanced technology & growing investment in healthcare. Also, growing reimbursement programs & growing awareness of the benefits of capillary blood collection is anticipated to fuel market growth further over the forecast period.

However, the Asia Pacific region is anticipated to grow with the highest CAGR over the forecast period. India, Japan & China are the major countries where demand for capillary blood collection devices is high, as the government is spending heavily on the healthcare sector in these regions. Also, technological advancement and increased medical research in Japan have widened the demand for capillary blood collection devices in the Asia Pacific.

Some of the major players operating in this industry are Abbott Laboratories, B. Braun Melsungen AG, Becton, Dickinson and Company (BD), Bio-Rad, Cardinal Health, Danaher Coproration, F. Hoffmann-La Roche AG, Greiner Bio One International GmbH, Haemonetics, HLT-STREFA S.A., Improve Medical, KABE LABORTECHNIK GmbH, Medtronic PLC, Novo Nordisk, Nipro Europe NV, Owen Mumford Ltd., SARSTEDT AG & Co. KG, Terumo Medical Corp., Thermo Fisher Scientific, Inc., Ypsomed Holding AG among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031

Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19.

03 December 2020

Read

Visiongain Publishes Drugs of Abuse Testing Market Report 2021-2031

Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise over the forecast period. The increase in the drugs abuse creates a huge demand for the drugs of abuse testing products.

03 December 2020

Read

Visiongain Publishes Controlled Substance Market Report 2021-2031

Continuous increasing prevalence of chronic pain is increasing demand for controlled substance as treatment for Chronic pain. Due to which increasing prevalence of chronic pain around the world is working as a driver for the controlled substance market.

03 December 2020

Read

Visiongain Publishes Companion Animal Diagnostics Market Report 2021-2031

All regions are facing rapid growth in the companion animal population. Companion animal are at high risk of developing various diseases for which companion animal require timely diagnosis for the identification, detection and treatment for life causing diseases.

03 December 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever